<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02184273</url>
  </required_header>
  <id_info>
    <org_study_id>1093.18</org_study_id>
    <nct_id>NCT02184273</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Nolotil i.v. vs. Placebo i.v. in the Prevention of Postoperative Pain in Children Undergoing Minor Surgery</brief_title>
  <official_title>Randomized, Double Blind, Comparative Trial of the Efficacy and Tolerability of Nolotil i.v. vs. Placebo i.v. in the Prevention of Postoperative Pain in Children of 6 and 11 Years Old Undergoing Minor Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to assess the analgesic efficacy in the prevention of postoperative pain in children
      undergoing minor surgery (herniorraphy, tonsillectomy) and to assess the tolerability of
      Metamizol in this group of patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <primary_completion_date type="Actual">March 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of children requiring rescue medication</measure>
    <time_frame>up to 4 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from drug administration, end of surgery and first patient's awake to the administration of rescue medication</measure>
    <time_frame>up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of children who require rescue medication</measure>
    <time_frame>up to 2 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the pain intensity by the patient by means of a Visual Analogue Scale (VAS)</measure>
    <time_frame>up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the pain intensity by the patient by means of a four points Verbal Rating Scale (VRS)</measure>
    <time_frame>up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the state of the patient by the guardian by means of the Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) test</measure>
    <time_frame>up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the partial efficacy by the investigator by means of a four points VRS</measure>
    <time_frame>up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the total efficacy by the investigator by means of a four points VRS</measure>
    <time_frame>after 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events (AE)</measure>
    <time_frame>up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of withdrawals due to AEs</measure>
    <time_frame>up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the total tolerability of the assigned treatment by the investigator by means of a four points VRS</measure>
    <time_frame>after 4 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Magnesium metamizol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium metamizol</intervention_name>
    <arm_group_label>Magnesium metamizol</arm_group_label>
    <other_name>Nolotil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children of either sex between 6 and 11 years of age

          -  Patients undergoing routine inguinal hernia repair or tonsillectomy

          -  Written informed consents by the guardian, according to the guidelines of Good
             Clinical Practice and current legislation

          -  The ability of the patient to understand and carry out the visual analogue scale
             assessments

          -  Patients with a physical status American Society of Anesthesiologist I or II class

        Exclusion Criteria:

          -  The use of any drug with analgesic properties in the 24 hours prior to the
             administration of the study drug

          -  Surgery with a foreseen duration over 60 minutes

          -  Patients with a nutritional index of less than 90 or greater than 120

          -  Patients with a body mass index which was not between the 3rd centile and the 97th
             centile for age

          -  Patients with any illness or malformation (except hernia) which, in the doctor's
             opinion, contraindicated the use of metamizol (aplastic anemia, agranulocytosis of a
             toxicological etiology, severe renal disease, etc.)

          -  Patients who have received in the previous 7 days or need currently anticoagulant
             treatment

          -  Significant allergy or known hypersensitivity to metamizol, its excipients and/or to
             other nonsteroidal antiinflammatory drugs

          -  Patients in whom the anesthetic regimen required by the protocol cannot be used

          -  Patients who have participated in another clinical trial in the past four weeks or are
             currently participating in another clinical trial

          -  Patients with any psychological disturbance which, in the investigator's opinion makes
             the patient unsuitable for inclusion in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2014</study_first_submitted>
  <study_first_submitted_qc>July 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2014</study_first_posted>
  <last_update_submitted>July 9, 2014</last_update_submitted>
  <last_update_submitted_qc>July 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dipyrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

